Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae

Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria

(2009) W. Haas et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study

(2009) Paul Karpecki et al.   CLINICAL THERAPEUTICS

Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis

(2009) Michael E. Tepedino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli

(2009) E. Cambau et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ocular Pharmacokinetics of Besifloxacin Following Topical Administration to Rabbits, Monkeys, and Humans

(2009) Joel W. Proksch et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% Compared with Moxifloxacin Ophthalmic Solution 0.5% for Treating Bacterial Conjunctivitis

(2009) Marguerite B. McDonald et al.   OPHTHALMOLOGY

Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones

(2008) M Yamada et al.   BRITISH JOURNAL OF OPHTHALMOLOGY